Key Points
- Dianthus Therapeutics EVP Ryan Savitz sold 31,249 shares on July 9 at an average price of $101.03, for total proceeds of about $3.16 million. The sale cut his direct ownership by 50% and was disclosed in an SEC filing.
- DNTH has surged near its 52-week high, opening at $98.64 versus a year-low of $18.08 and a high of $102.33. The company now has a market cap of about $5.39 billion.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $117.82. Recent earnings also beat estimates, though the company remains unprofitable.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 31,249 shares of the firm's stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares of the company's stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Dianthus Therapeutics Price Performance
DNTH opened at $98.64 on Tuesday. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $102.33. The firm's fifty day moving average price is $87.98 and its two-hundred day moving average price is $72.34. The company has a market capitalization of $5.39 billion, a P/E ratio of -23.88 and a beta of 1.20.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.
Wall Street Analyst Weigh In
DNTH has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Wells Fargo & Company started coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an "overweight" rating and a $135.00 price objective on the stock. Raymond James Financial restated a "strong-buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. William Blair reaffirmed an "outperform" rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Finally, Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $117.82.
Read Our Latest Stock Analysis on DNTH
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of DNTH. Wellington Management Group LLP boosted its holdings in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock worth $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP increased its holdings in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. State Street Corp increased its holdings in Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company's stock valued at $62,129,000 after purchasing an additional 836,571 shares in the last quarter. Braidwell LP bought a new position in Dianthus Therapeutics in the 3rd quarter valued at $32,859,000. Finally, Polar Capital Holdings Plc bought a new position in Dianthus Therapeutics in the 3rd quarter valued at $29,434,000. Institutional investors own 47.53% of the company's stock.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
